Novo-Catalent antitrust clearance could be problem for other, 'smaller players,' says CEO of Novo rival Roche
MLex Summary: Greenlighting pharmaceutical company Novo Holding's acquisition of contract drug manufucturer Catalent would be the "wrong" decision for antitrust authorities because "limiting the competition in this space is not a...To view the full article, register now.
Already a subscriber? Click here to view full article